The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Cozac V.V.

Hospital of the University of Basel, Basel, Switzerland

Modern approaches to treatment of psychosis in Parkinson’s disease

Authors:

Cozac V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10): 103‑109

DOI: 10.17116/jnevro2016116101103-109

Read: 7180 times

Download PDF (RU)
Contact the author
Table of contents

MODERN APPROACHES TO TREATMENT OF PSYCHOSIS IN PARKINSON’S DISEASE
MODERN APPROACHES TO TREATMENT OF PSYCHOSIS IN PARKINSON’S DISEASE

To cite this article:

Cozac VV. Modern approaches to treatment of psychosis in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10):103‑109. (In Russ.)
https://doi.org/10.17116/jnevro2016116101103-109

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):15-22
Asso­ciation of inflammation and chro­nic fati­gue syndrome in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):79-87
Electric acti­vity of the brain at early and late clinical stages of expe­rimental mode­ling of Parkinson’s disease, an impact of hema­ntane. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):129-134
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Chro­nic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112
Abstract:

Psychotic disorders in Parkinson’s disease (PDPD) are common and significantly influence the quality of life and disability level. The pathogenesis of PDPD is complex and not yet fully understood. Taking into consideration the features of the Parkinson’s disease (usually older patients with a risk of cognitive decline), and the pharmacodynamics of the antiparkinsonian and traditional antipsychotic drugs, the management of PDPD is a challenging issue of clinical neurology and psychiatry. In this systematic review, scientific publications for the period 2014—2016 were analyzed within two bibliographic databases: MEDLINE/PubMed and eLIBRARY.RU. Additionally, the guidelines of the International Parkinson and Movement Disorders Society, American Academy of Neurology and European Academy of Neurology were included in the analysis. Clozapine is recommended to use in the treatment of PDPD, quetiapine is possible to use, pimavanserin will probably become a remedy of choice. Nonpharmacological approaches have positive effects on the general condition of the patients with PDPD, however the efficacy of such approaches to treat psychosis is unclear.

Keywords:

Parkinson’s disease
psychosis
systematic review

Authors:

Cozac V.V.

Hospital of the University of Basel, Basel, Switzerland

Close metadata

References:

  1. Capriotti T, Terzakis K. Parkinson Disease. Home Healthcare Now. 2016;34(6):300-307. doi: 10.1097/NHH.0000000000000398
  2. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism and Related Disorders. 2011;17(10):717-723. doi: 10.1155/2016/4370674
  3. Broadstock M, Ballard C, Corbett A. Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease. Expert Review of Clinical Pharmacology. 2014;7(6):779-786. doi: 10.1586/17512433.2014.966814
  4. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 1999;67(4):492-496. doi: 10.1136/jnnp.67.4.492
  5. Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism and Related Disorders. 2010;16(9):553-560. doi: 10.1016/j.parkreldis.2010.05.004
  6. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of «benign hallucinations» in Parkinson disease. Archives of Neurology. 2006;63(5):713-716. doi: 10.1001/archneur.63.5.713
  7. Nodel' MR. Vlijanie nervno-psihicheskih narushenij na kachestvo zhizni pacientov s bolezn'ju Parkinsona. Nevrologicheskij zhurnal. 2015;20(1):20-27. doi: 10.18821/1560-9545-2015-20-1-20-27
  8. Grün D, Pieri V, Vaillant M, Diederich NJ. Journal of the American Medical Directors Association. 2016. doi: 10.1016/j.jamda.2016.03.004
  9. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Movement Disorders. 2007;22:1061-1068. doi: 10.1002/mds.21382
  10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry. 1992;55:181-184. doi: 10.1136/jnnp.55.3.181
  11. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. Journal of the Neurological Sciences. 2010;289(1-2):12. doi: 10.1016/j.jns.2009.08.014
  12. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 2001;70(6):734-738. doi: 10.1136/jnnp.70.6.734
  13. Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendentte M, Rios Romenets S, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson’s disease: A prospective study. Movement Disorders. 2012;27(6):720. doi: 10.1002/mds.24939
  14. Kiziltan G, Ozekmekci S, Ertain S, Ertain T, Erginoz E. Relationship between age and subtypes of psychotic symptoms in Parkinson’s disease. Journal of Neurology. 2007;254(4):448-452. doi: 10.1007/s00415-006-0388-4
  15. Ecker D, Unrath A, Kassubek J, Sabolek K. Dopamine agonists and their risk to induce psychotic episodes in Parkinson’s disease: A case control study. BMC Neurology. 2009;9:23. doi: 10.1186/1471-2377-9-23
  16. Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R et al. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurology. 2013;13:145. doi: 10.1186/1471-2377-13-145
  17. Forsaa EB, Larsen JP,Wentzel-Larsen T, Goetz CG, Glenn T, Stebbins T et al. A 12-year population based study of psychosis in Parkinson disease. Archives of Neurology. 2010;67:996-1001. doi: 10.1001/archneurol.2010.166
  18. Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, Perez J, Ribosa-Nogué R, Marín J et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Movement Disorders. 2016;31(1):45-52. doi: 10.1002/mds.26432
  19. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66:93-98. doi: 10.1212/01.wnl.0000191325.31068.c4
  20. Fernandez H, Lio FM, Kaiser JJ, Davis P, Peters H, Williams D et al. P1.181 Parkinson’s disease psychosis (PDP): an under-diagnosed condition in spite of its prevalence and impact. Parkinsonism and Related Disorders. 2009;15(suppl 2):75. doi: 10.1016/s1353-8020(09)70303-7
  21. Grover S, Somaiya M, Kumar S, Avasthi A. Journal of Neurosciences in Rural Practice. 2015;6(1):65-76. doi: 10.4103/0976-3147.143197
  22. Mack JL, Rabins PV, Anderson K, Goldstein S, Grill S, Elaina S et al. Prevalence of psychotic symptoms in a community-based Parkinson’s disease sample. The American Journal of Geriatric Psychiatry. 2012;20:123-131. doi: 10.1097/jgp.0b013e31821f1b41
  23. Hindle JV. The practical management of cognitive impairment and psychosis in the older Parkinson’s disease patient. Journal of Neural Transmission. 2013;120:649-653. doi: 10.1007/s00702-013-0994-0
  24. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behavioral Brain Research. 2011;221:564-573. doi: 10.1016/j.bbr.2009.12.048
  25. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Archives of Neurology. 2010;67:416-421. doi: 10.1001/archneurol.2010.35
  26. Gama RL, Bruin VM, Tavora DG, Duran FLS, Bittencourt L, Tufik S. Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: a comparative voxel-based analysis. Brain and Cognition. 2014;87:97-103. doi: 10.1016/j.bandc.2014.03.011
  27. Friedman JH. Parkinson disease psychosis: Update. Behavioural Neurology. 2013;27:469-477. doi: 10.3233/BEN-129016
  28. Borek LL, Friedman JH. Treating psychosis in movement disorder patients: a review. Expert Opinion on Pharmacotherapy. 2014;15(11):1553-1564. doi: 10.1517/14656566.2014.918955
  29. Akbar U, Friedman JH. Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease. Expert Review of Neurotherapeutics. 2015;15(9):1053-1065. doi: 10.1586/14737175.2015.1077703
  30. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH.Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clinical Neuropharmacology. 2005;28(5):215-219. doi: 10.1097/01.wnf.0000180228.77802.32
  31. Aarsland D, Marsh L, Schrag A. Neuropsychiatric Symptoms in Parkinson’s Disease. Movement Disorders. 2009;24(15):2175-2186. doi: 10.1002/mds.22589
  32. Pagonabarraga J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, Kulisevsky J. A prospective study of delusional misidentification syndromes in Parkinson’s disease with dementia. Movement Disorders. 2008;23:443-448. doi: 10.1002/mds.21864
  33. U.S. National Library of Medicine®, National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/pubmed/
  34. Электронная библиотека научных публикаций, http://elibrary.ru / Jelektronnaja biblioteka nauchnyh publikacij, http://elibrary.ru (In Russ.).
  35. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Andersonet K et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia. Subcommittee of the American Academy of Neurology in Parkinson disease (an evidence-based review): Report of the Quality Standards. Neurology. 2006;66;996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d
  36. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. European Journal of Neurology. 2013;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x
  37. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders. 2011;26(suppl 3):42-80. doi: 10.1002/mds.23884
  38. Connoly B, Fox SH. Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease. Neurotherapeutics. 2014;11:78-91. doi: 10.1007/s13311-013-0238-x
  39. Cooney WJ, Stacy M. Neuropsychiatric Issues in Parkinson’s Disease. Current Neurology and Neuroscience Reports. 2016;16:49. doi: 10.1007/s11910-016-0647-4
  40. Goldman JG, Holden S. Treatment of Psychosis and Dementia in Parkinson’s Disease. Current Treatment Options in Neurology. 2014;16(3):281. doi: 10.1007/s11940-013-0281-2
  41. Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochemical Research. 2014;39(10):2008-2017. doi: 10.1007/s11064-014-1293-3
  42. Levin J, Hasan A, Höeglinger GU. Psychosis in Parkinson’s disease: identification, prevention and treatment. Journal of Neural Transmission. 2016;123:45-50. doi: 10.1007/s00702-015-1400-x
  43. Wand APF, Peisah C. Managing psychosis in Parkinson’s disease without drugs Neurodegenerative Disease Management. 2015;5(4):271-274. doi: 10.2217/nmt.15.27
  44. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540. doi: 10.1016/s0140-6736(13)62106-6
  45. Hack N, Fayad SM, Monari EH, Akbar U, Hardwick A, Rodriguez RL et al. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS One. 2014;9(3):91545. doi: 10.1371/journal.pone.0091545
  46. Fox SH. Pimavanserin as treatment for Parkinson's disease psychosis. Lancet. 2014;383(9916):494-496. doi: 10.1016/S0140-6736(13)62157-1
  47. Пресс-релиз. U.S. Food and Drug Administration. Загружен 01.05.16. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm
  48. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophrenia Research. 2012;141(2-3):144-152. doi: 10.1016/j.schres.2012.07.02
  49. Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. The Journal of ECT. 2010;26:111-115. doi: 10.1097/yct.0b013e3181c18a3d
  50. Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishiet A et al. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35:1704-1708. doi: 10.1016/j.pnpbp.2011.05.003
  51. Nishioka K, Tanaka R, Shimura H, Hirano K, Hatano T, Miyakawa K et al. Quantitative evaluation of electroconvulsive therapy for Parkinson’s disease with refractory psychiatric symptoms. Journal of Neural Transmission. 2014;121(11):1405-1410. doi: 10.1007/s00702-014-1212-4
  52. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Movement Disorders. 2003;18(7):831-838. doi: 10.1002/mds.10450
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.